DK3860620T3 - Formulering omfattende ozoniseret olie til behandling af en tumor - Google Patents

Formulering omfattende ozoniseret olie til behandling af en tumor Download PDF

Info

Publication number
DK3860620T3
DK3860620T3 DK19795326.8T DK19795326T DK3860620T3 DK 3860620 T3 DK3860620 T3 DK 3860620T3 DK 19795326 T DK19795326 T DK 19795326T DK 3860620 T3 DK3860620 T3 DK 3860620T3
Authority
DK
Denmark
Prior art keywords
tumor
formulation
treatment
ozonized oil
ozonized
Prior art date
Application number
DK19795326.8T
Other languages
English (en)
Inventor
Giancarlo Carocci
Original Assignee
O3 Zone Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by O3 Zone Ltd filed Critical O3 Zone Ltd
Application granted granted Critical
Publication of DK3860620T3 publication Critical patent/DK3860620T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7004Stress
    • G01N2800/7009Oxidative stress

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
DK19795326.8T 2018-10-01 2019-09-30 Formulering omfattende ozoniseret olie til behandling af en tumor DK3860620T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102018000009063A IT201800009063A1 (it) 2018-10-01 2018-10-01 Formulazione comprendente olio ozonizzato nel trattamento di un tumore
PCT/IB2019/058298 WO2020070623A1 (en) 2018-10-01 2019-09-30 Formulation comprising ozonised oil in the treatment of a tumour

Publications (1)

Publication Number Publication Date
DK3860620T3 true DK3860620T3 (da) 2024-02-12

Family

ID=64607215

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19795326.8T DK3860620T3 (da) 2018-10-01 2019-09-30 Formulering omfattende ozoniseret olie til behandling af en tumor

Country Status (21)

Country Link
US (1) US20210393675A1 (da)
EP (1) EP3860620B1 (da)
JP (1) JP2022508564A (da)
KR (1) KR20210068455A (da)
CN (1) CN112912085A (da)
AU (1) AU2019351949A1 (da)
BR (1) BR112021005972A2 (da)
CA (1) CA3113574A1 (da)
DK (1) DK3860620T3 (da)
EA (1) EA202190753A1 (da)
ES (1) ES2970191T3 (da)
FI (1) FI3860620T3 (da)
HR (1) HRP20240235T1 (da)
IL (1) IL281886B1 (da)
IT (1) IT201800009063A1 (da)
LT (1) LT3860620T (da)
MX (1) MX2021003651A (da)
PL (1) PL3860620T3 (da)
PT (1) PT3860620T (da)
RS (1) RS65217B1 (da)
WO (1) WO2020070623A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201804452A2 (tr) * 2018-03-29 2018-06-21 Ahmet Uemit Sabanci Ozonlanmiş yağ i̇çeren solüsyonlar
IT202100020849A1 (it) * 2021-08-03 2023-02-03 Moss Pharma S R L Nuovo uso di olio ozonizzato

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23467A1 (es) * 2002-04-08 2009-12-17 Cnic Ct Nac Investigaciones Procedimiento para la obtención de aceites y grasas vegetales ozonizados para fines farmacéuticos y cosmetológicos
WO2008050157A2 (en) * 2006-10-24 2008-05-02 Steven Karim Ozonated oil formulations
CL2009000138A1 (es) * 2009-01-23 2009-05-29 Tapia Patricia Alejandra Rojas Proceso de elaboracion de una composicion ozonizada que consta de tres fases e incluye un doble proceso de ozonizacion de una o mas de sus materias primas naturales y/o sinteticas; util para oxigenar, nutrir, hidratar, reparar y generar el tejido celular.
CN106265722A (zh) * 2016-11-01 2017-01-04 侯建生 臭氧化油在癌症防治中的应用

Also Published As

Publication number Publication date
FI3860620T3 (fi) 2024-02-15
ES2970191T3 (es) 2024-05-27
CN112912085A (zh) 2021-06-04
MX2021003651A (es) 2021-05-28
JP2022508564A (ja) 2022-01-19
IT201800009063A1 (it) 2020-04-01
US20210393675A1 (en) 2021-12-23
EP3860620B1 (en) 2023-12-06
CA3113574A1 (en) 2020-04-09
EP3860620A1 (en) 2021-08-11
PT3860620T (pt) 2024-02-09
WO2020070623A1 (en) 2020-04-09
KR20210068455A (ko) 2021-06-09
LT3860620T (lt) 2024-02-26
IL281886B1 (en) 2024-03-01
IL281886A (en) 2021-05-31
EA202190753A1 (ru) 2021-06-28
HRP20240235T1 (hr) 2024-05-24
PL3860620T3 (pl) 2024-04-29
AU2019351949A1 (en) 2021-05-20
RS65217B1 (sr) 2024-03-29
BR112021005972A2 (pt) 2021-06-29

Similar Documents

Publication Publication Date Title
DK3570844T3 (da) Azolopyrimidin til behandlingen af kræftrelaterede lidelser
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
DK3431105T3 (da) Medicinsk sammensætning til behandling af cancer
DK3439635T3 (da) Formuleringer til behandling af fast tumor
DK3728271T3 (da) Makrocykliske forbindelser til behandling af sygdomme
DK3173092T3 (da) Rna-holdig sammensætning til behandling af tumorsygdomme
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
DK3600270T3 (da) Forbindelser og sammensætninger til behandling af hæmatologiske lidelser
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
GB201804514D0 (en) Treatment of pyroptosis
DK3524255T3 (da) Sammensætning til behandling af acne
DK3498278T3 (da) Forbindelser til behandling af sygdomme relateret til DUX4-ekspression
DK3081263T3 (da) Sammensætninger og redskaber til behandling af glaukom
DK3400072T3 (da) Formuleringer til behandling af blærecancer
DK3430143T3 (da) Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme
DK3870578T3 (da) Terapeutiske forbindelser
DK3328864T3 (da) Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser
DK3286317T3 (da) Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi
DK3897672T5 (da) Hbv kombinationsbehandling
DK3478713T3 (da) Sammensætninger til behandling af amyloidose
DK3468604T3 (da) Farmaceutiske kombinationer til behandling af cancer
DK3506901T3 (da) Anvendelse af kynurensyre til behandling af muskelatrofi
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
DK3724173T3 (da) Forbindelser til behandling af neuromuskulære lidelser
DK3403674T3 (da) Farmaceutiske sammensætninger til behandling af smerte